Payment overview · 2025
General Payments
$40.99
2 reported records · 2 companies
Healthcare provider profile · identity verified
William Charles Husum, MD
Allopathic & Osteopathic Physicians|General Practice · MEDFORD, OR · NPI 1528082666
Verified facts
What the public records show
CMS Open Payments records show William Charles Husum, MD received $40.99 in general payments during 2025 across 2 reported records.
Gilead Sciences, Inc. accounted for 60.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $24.90 | 60.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.09 | 39.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $40.99 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
70 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrochlorothiazide | Hydrochlorothiazide | 369 | 115 |
| Omeprazole | Omeprazole | 366 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 362 | 110 |
| Atorvastatin Calcium | Atorvastatin Calcium | 360 | 116 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 269 | 91 |
| Simvastatin | Simvastatin | 227 | 69 |
| Losartan Potassium | Losartan Potassium | 224 | 80 |
| Potassium Chloride | Potassium Chloride | 224 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 214 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 211 | 74 |
| Valsartan | Valsartan | 207 | 67 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 199 | 55 |
| Lisinopril | Lisinopril | 165 | 60 |
| Furosemide | Furosemide | 150 | 62 |
| Eliquis | Apixaban | 140 | 44 |
| Allopurinol | Allopurinol | 135 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 132 | 40 |
| Warfarin Sodium | Warfarin Sodium | 115 | 31 |
| Gabapentin | Gabapentin | 107 | 28 |
| Metformin Hcl | Metformin Hcl | 107 | 35 |
| Atenolol | Atenolol | 106 | 31 |
| Lorazepam | Lorazepam | 88 | 25 |
| Metformin Hcl Er | Metformin Hcl | 88 | 22 |
| Sertraline Hcl | Sertraline Hcl | 82 | 25 |
| Estradiol | Estradiol | 79 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 77 | 27 |
| Alprazolam | Alprazolam | 75 | 27 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 74 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 25 |
| Synthroid | Levothyroxine Sodium | 70 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 69 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 62 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 21 |
| Azithromycin | Azithromycin | 59 | 41 |
| Carvedilol | Carvedilol | 56 | 19 |
| Prednisone | Prednisone | 54 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 14 |
| Jardiance | Empagliflozin | 52 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 52 | 14 |
| Finasteride | Finasteride | 46 | 11 |
| Ozempic | Semaglutide | 44 | suppressed |
| Diazepam | Diazepam | 43 | suppressed |
| Mounjaro | Tirzepatide | 43 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 40 | 13 |
| Cephalexin | Cephalexin | 36 | 27 |
| Ezetimibe | Ezetimibe | 35 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 35 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 32 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 27 | 21 |
| Celecoxib | Celecoxib | 26 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 25 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 15 |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 15 |
| Irbesartan | Irbesartan | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $40.99 · 2 records | Gilead Sciences, Inc. | QULIPTA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error